Search Videos by Topic or Participant
Browse by Series:

Transplantation in Deletion 5q Myelodysplastic Syndromes

Panelists: Thomas Prebet, MD, PhD.
Published: Thursday, Jul 23, 2015


Transplantation should be considered up front in any patient with myelodysplastic syndrome (MDS), says Thomas Prebet, MD, PhD, although factors, such as disease, patient age, and comorbidities, may prevent some individuals from receiving such therapy.

In a case scenario, Prebet describes a 45-year-old woman with deletion 5q (del 5q) MDS who initially did not require any transfusions during the beginning of her disease. After a few months, she became transfusion dependent and experienced iron overload but was otherwise without severe consequences. After 2 years of transplantation, she remained transfusion free. This exemplifies what can be achieved for patients with the use of transplantation, comments Prebet, even in individuals with del 5q MDS, who are less likely to receive transfusions.
Slider Left
Slider Right


Transplantation should be considered up front in any patient with myelodysplastic syndrome (MDS), says Thomas Prebet, MD, PhD, although factors, such as disease, patient age, and comorbidities, may prevent some individuals from receiving such therapy.

In a case scenario, Prebet describes a 45-year-old woman with deletion 5q (del 5q) MDS who initially did not require any transfusions during the beginning of her disease. After a few months, she became transfusion dependent and experienced iron overload but was otherwise without severe consequences. After 2 years of transplantation, she remained transfusion free. This exemplifies what can be achieved for patients with the use of transplantation, comments Prebet, even in individuals with del 5q MDS, who are less likely to receive transfusions.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x